Environment
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
StatePennsylvaniaReferred
SR 365: A Resolution recognizing the month of September 2026 as "Polycystic Kidney Disease Awareness Month" in Pennsylvania.
Rosemary Brown
SR 365 status: Referred — Referred to Rules & Executive Nominations (updated Sep 10, 2026).
Source
OpenStates
Confidence
Low
Analysis basis
OpenStates summary
01
What this bill does
Official summary alongside an AI-generated read on where it stands and why.
Overall Score
60OUT OF 100
Score:60/100 civic fit
Risk:Low Risk
Impact:Low Impact 5/100
Constitutionality100%
Bipartisan100%
Public opinion100%
Bill summary
What changes
The state legislature would formally designate September 2026 as 'Polycystic Kidney Disease Awareness Month.'
Who is affected
No specific population is legally impacted; the resolution is directed at general public awareness.
Requirements and enforcement
None; there are no regulatory or compliance requirements created by this resolution.
Costs and funding
Not stated, though typical for legislative resolutions, fiscal impact is negligible.
When it takes effect
September 2026.
Potential benefits
Supports public awareness and recognition for individuals affected by Polycystic Kidney Disease.
Risks and tradeoffs
The resolution provides only symbolic recognition and does not offer material support or health-system improvements.
What is still unknown
No significant unknowns as the scope of the bill is limited to formal recognition.
02
Impact analysis
✦ AI analysisModeled effects across six domains, estimated from bill text and comparable legislation.
Economy
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Society
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Technology Industry
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Civic Accountability
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Public Health & Safety
Positive outlook
60%
Benefits
- Increases visibility of Polycystic Kidney Disease (PKD)
- Promotes public education about rare genetic conditions
- Supports patient advocacy and community engagement efforts
Risks
- Resolution carries no legal force to improve treatment access
- Symbolic recognition does not allocate clinical resources
- Does not mandate screening or medical intervention protocols
03
How trustworthy & consequential it is
Sourcing already shown above, this is what the analysis found worth flagging.
Source
OpenStates
Official bill text or data from OpenStates.
Confidence
Low
Information is limited or incomplete.
Analysis basis
OpenStates summary
Source used for this bill's analysis.
Source note
This measure is symbolic and provides no specific public health funding or policy reform
Analysis scope
Analysis based solely on a high-level legislative abstract
04
Where it stands
Official record- IntroducedComplete
- CommitteeCurrent
- Chamber votesUpcoming
- Final agreementUpcoming
- GovernorUpcoming
- EnactedUpcoming
05
How it affects your district
✦ Personalized
Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.
06
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.